Revisions to Brazil's drug price framework are coming - what's included and what's missing? Our analysts provide th… https://t.co/8s17gnKCXf
IHS @ ISPOR – Please visit us at Table TT2 on the 5th floor
IHS Life Sciences is pleased to announce that we will be at the 20th Annual International Meeting, May 16-20 at the Philadelphia Marriott. Come by TT2 to meet members of our team and learn about our solutions and latest research.
We will have 2 posters on display:
Session I on Monday, 18 May, 8:30 a.m. - 2:15 p.m.
Poster Author Discussion Hour: 1:15 a.m. - 2:15 p.m.
PDB45: The Clinical and Economic Value of a Digital Lifestyle Intervention Program in the PreDiabetes Population: Case Study with the 'Prevent' Program
by Su W, Dall T, Chen F, Iacobucci W,
Session V on Wednesday, 10 May, 8:30 a.m. - 2:15 p.m.
Poster Author Discussion Hour: 12:45 p.m. - 1:45 p.m.
PSY34 Projecting Benefits from Weight Loss in Obese Populations: A Microsimulation Approach
by Chen F, Iacobucci W, Su W, Dall T
We will be posting here on the blog as well as tweeting @IHS4LifeSciences. We look forward to seeing you in Philly!
Gustav Ando is the director of life sciences at IHS
Posted 7 May 2015
- Brazil finally edges towards first drug pricing reform after two years – is it a missed opportunity?
- Will IRP upend Czech orphan drug reforms?
- Variations on an IRP theme: How payers are repurposing pricing policies for new categories of medicines
- Pharmaceutical and healthcare sectors jointly top global PMI ranking for first time
- Will physicians become more difficult to find in America?
- California's Medicaid pharmacy "carve-out" set to boost state's negotiating power, introduce IRP for drugs
- Trend towards HTA collaboration boosts need for data
- Barriers to market access for innovative medicines increase in the COVID era
Major changes to Czech P&R regulations for orphan and high-cost drugs set to expand access. What role will IRP play… https://t.co/bQcVCG5jut